CN103405419A - Application of Chukrasone B in medicine for treating prostatic cancer - Google Patents
Application of Chukrasone B in medicine for treating prostatic cancer Download PDFInfo
- Publication number
- CN103405419A CN103405419A CN201310386097XA CN201310386097A CN103405419A CN 103405419 A CN103405419 A CN 103405419A CN 201310386097X A CN201310386097X A CN 201310386097XA CN 201310386097 A CN201310386097 A CN 201310386097A CN 103405419 A CN103405419 A CN 103405419A
- Authority
- CN
- China
- Prior art keywords
- chukrasone
- prostatic cancer
- application
- medicine
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229930187319 chukrasone Natural products 0.000 title claims abstract description 25
- 239000003814 drug Substances 0.000 title claims abstract description 13
- 206010060862 Prostate cancer Diseases 0.000 title abstract description 15
- 208000000236 Prostatic Neoplasms Diseases 0.000 title abstract description 13
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 claims description 7
- 201000001514 prostate carcinoma Diseases 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 abstract description 10
- 230000012010 growth Effects 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 5
- 230000005764 inhibitory process Effects 0.000 abstract description 4
- 230000000259 anti-tumor effect Effects 0.000 abstract description 2
- 238000011161 development Methods 0.000 abstract description 2
- 238000011156 evaluation Methods 0.000 abstract description 2
- 101150030514 GPC1 gene Proteins 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 241001156380 Chukrasia tabularis Species 0.000 description 2
- 102000006628 Kv1.2 Potassium Channel Human genes 0.000 description 2
- 108010087141 Kv1.2 Potassium Channel Proteins 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses application of Chukrasone B in preparation of a medicine for treating prostatic cancer, and belongs to the technical field of new application of medicines. The in-vitro MTT (3-4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) antitumor activity evaluation shows that Chukrasone B has remarkable inhibition effect on the growth of human prostatic cancer cell lines ALVA, gpc-1, 9L-B and Du145, so that Chukrasone B has a good development and application prospect and can be applied to the preparation of the medicine for treating prostatic cancer. The application of Chukrasone B in the preparation of the medicine for treating prostatic cancer is disclosed for the first time; the framework type of Chukrasone B is brand new; Chukrasone B brings unexpected inhibition activity for prostatic cancer cells.
Description
Technical field
The present invention relates to the new purposes of Compound C hukrasone B, relate in particular to the application of Chukrasone B in preparing antiprostate cancer.
Technical background
Cancer is to one of disease of human life's health hazard maximum, and annual have a large amount of people to die from cancer.The research and development of cancer therapy drug are the focuses of study of pharmacy always.In antitumor drug, having 74% to be the natural product or derivatives thereof, is exactly the reasonable antitumor drug of effect clinically at present as paclitaxel and derivant thereof.Therefore, from searching anticancer compound or lead compound natural product, have great importance.
The Compound C hukrasone B the present invention relates to is one and delivered (Liu in 2012, H.B.et al., 2012.Chukrasones A and B:Potential Kv1.2Potassium Channel Blockers with New Skeletons from Chukrasia tabularis.Organic Letters14 (17), 4438 – 4441.) New skeleton compound, this compound has brand-new framework types, current purposes only relates to potassium-channel and suppresses active, for the purposes of the Chukrasone B the present invention relates in preparation treatment carcinoma of prostate medicine, belong to open first, because framework types belongs to brand-new framework types, and its inhibition for prostate gland cancer cell is active unexpectedly strong, there do not is the possibility that is provided any enlightenment by other compounds, possesses outstanding substantive distinguishing features, control for carcinoma of prostate simultaneously obviously has significant progress.
Summary of the invention
The invention provides the application of Compound C hukrasone B in preparing antitumor drug.
The present invention adopts following technical scheme: the application of Chukrasone B in preparing antiprostate cancer, and the structural formula of Chukrasone B is as shown in formula I:
The present invention finds by external MTT anti-tumor activity evaluation, and Chukrasone B also has significant inhibitory action to the growth of human prostate cancer cell line ALVA, gpc-1,9L-B and Du145, suppresses the IC of this 4 strain Growth of Cells
50Value is respectively 1.31 ± 0.13 μ M, 0.69 ± 0.09 μ M, 2.17 ± 0.55 μ M and 1.03 ± 0.16 μ M.Therefore, Chukrasone B can, for the preparation of antiprostate cancer, have good development prospect.
The purposes of the Chukrasone B the present invention relates in preparation treatment carcinoma of prostate medicine belongs to open first, because framework types belongs to brand-new framework types, and its inhibition for prostate gland cancer cell is active unexpectedly strong, there do not is the possibility that is provided any enlightenment by other compounds, possess outstanding substantive distinguishing features, the control for carcinoma of prostate simultaneously obviously has significant progress.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but be limited by claim.
The specific embodiment
The preparation method of Compound C hukrasone B involved in the present invention is referring to document (Liu, H.B.et al., 2012.Chukrasones A and B:Potential Kv1.2Potassium Channel Blockers with New Skeletons from Chukrasia tabularis.Organic Letters14 (17), 4438 – 4441.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but be limited by claim.
Embodiment 1: the preparation of Compound C hukrasone B tablet involved in the present invention:
Get 20 and digest compound Chukrasone B, add conventional adjuvant 180 grams that prepare tablet, mix, conventional tablet machine is made 1000.
Embodiment 2: the preparation of Compound C hukrasoneB capsule involved in the present invention:
Get 20 and digest compound Chukrasone B, add the conventional adjuvant such as starch 180 grams that prepare capsule, mix, encapsulatedly make 1000.
Below by pharmacodynamic experiment, further illustrate its pharmaceutically active.
Experimental example: adopt the growth inhibited effect of mtt assay assessing compound Chukrasone B to human prostate cancer cell line
1. method: the cell that is in the growth logarithmic (log) phase: human prostate cancer cell line ALVA, gpc-1,9L-B and Du145(buy from Chinese Academy of Sciences's cell bank) with 1.5 * 10
4The concentration kind is in 96 orifice plates.After cell culture 24h is adherent, suck original culture medium.Test is divided into blank group, drug treating group.Blank group is changed 1640 culture medium that contain 10% hyclone; It is 100 μ M that the replacing of drug treating group contains concentration, 50 μ M, 10 μ M, 1 μ M, 0.1 μ M, the culture medium of the Chukrasone B of 0.01 μ M and 0.001 μ M.After cultivating 48h, add the MTT of concentration 5mg/mL, continue to be put in CO
2Incubator is cultivated 4h, then along culture fluid top, suck 100 μ L supernatants, add 100 μ L DMSO, 10min is placed in dark place, utilize microplate reader (Sunrise company product) to measure light absorption value (wavelength 570nm), and calculating the cell survival situation according to light absorption value, 6 repeating holes are established in each processing.Cell survival rate (%)=Δ OD
Drug treating/ Δ OD
Blank* 100.
2. result: Chukrasone B has significant inhibitory action to the growth of human prostate cancer cell line ALVA, gpc-1,9L-B and Du145.This compound suppresses the IC of human prostate cancer cell line ALVA, gpc-1,9L-B and Du145 growth
50Value is respectively: 1.31 ± 0.13 μ M, 0.69 ± 0.09 μ M, 2.17 ± 0.55 μ M and 1.03 ± 0.16 μ M.
By above-described embodiment, shown, Chukrasone B of the present invention has good inhibitory action to the growth of human prostate cancer cell line ALVA, gpc-1,9L-B and Du145.Prove thus, Chukrasone B of the present invention has the anti-prostate cancer activity, can be for the preparation of antiprostate cancer.
Claims (1)
1.Chukrasone the application of B in treatment carcinoma of prostate medicine, described Compound C hukrasone B structure as
Formula IShown in:
Formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310386097.XA CN103405419B (en) | 2013-08-29 | 2013-08-29 | The application of Chukrasone B in preparation treatment carcinoma of prostate medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310386097.XA CN103405419B (en) | 2013-08-29 | 2013-08-29 | The application of Chukrasone B in preparation treatment carcinoma of prostate medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103405419A true CN103405419A (en) | 2013-11-27 |
| CN103405419B CN103405419B (en) | 2016-02-03 |
Family
ID=49598494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310386097.XA Expired - Fee Related CN103405419B (en) | 2013-08-29 | 2013-08-29 | The application of Chukrasone B in preparation treatment carcinoma of prostate medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103405419B (en) |
-
2013
- 2013-08-29 CN CN201310386097.XA patent/CN103405419B/en not_active Expired - Fee Related
Non-Patent Citations (2)
| Title |
|---|
| LIU,H.B.等: "Chukrasone A and B: Potential Kv1.2 Potassium Channel Blockers with New Skeletons from Chukrasia tabularis", 《ORGANIC LETTERS》, vol. 14, no. 17, 31 December 2012 (2012-12-31) * |
| 王冬艳，等: "钾离子通道作为肿瘤治疗靶点的研究", 《国外医学药学分册》, vol. 33, no. 4, 31 August 2006 (2006-08-31) * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103405419B (en) | 2016-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103405418A (en) | Application of Chukrasone B in medicine for treating breast cancer | |
| CN103462960A (en) | Application of Incarviatone A in medicaments for treating prostatic cancer | |
| CN103405424A (en) | Application of Chukrasone B in medicine for treating colorectal cancer | |
| CN102861078B (en) | Application of Houttuynoid D in medicine for treating prostatic cancer | |
| CN102872109B (en) | Application of Houttuynoid A in medicament for treating prostate cancer | |
| CN103405419A (en) | Application of Chukrasone B in medicine for treating prostatic cancer | |
| CN103432140A (en) | Application of Chukrasone A in preparation of medicaments for treating endometrial cancer | |
| CN103405459A (en) | Application of Chukrasone A in medicaments for treating prostatic carcinoma | |
| CN103405414A (en) | Application of Chukrasone B in medicine for treating ileocecal cancer | |
| CN103405423A (en) | Application of Chukrasone B in medicine for treating renal cancer | |
| CN103405412A (en) | Application of Chukrasone B in medicine for treating laryngocarcinoma | |
| CN103405416A (en) | Application of Chukrasone B in medicine for treating endometrial cancer | |
| CN103405451A (en) | Application of Chukrasone A in medicaments for treating tongue carcinoma | |
| CN103405454A (en) | Application of Chukrasone A in medicaments for treating renal carcinoma | |
| CN103405410A (en) | Application of Chukrasone B in medicine for treating gastric cancer | |
| CN103405413A (en) | Application of Chukrasone B in medicaments for treating bladder cancer | |
| CN103405421A (en) | Application of Chukrasone B in medicine for treating cervical cancer | |
| CN103405420A (en) | Application of Chukrasone B in medicine for treating nasopharynx cancer | |
| CN103405449A (en) | Application of Chukrasone A in medicaments for treating breast carcinoma | |
| CN103405415A (en) | Application of Chukrasone B in medicine for treating pancreatic cancer | |
| CN103405444A (en) | Application of Chukrasone A in medicaments for treating bladder cancer | |
| CN103405452A (en) | Application of Chukrasone A in medicaments for treating gastric carcinoma | |
| CN103356575A (en) | Application of Sarcaboside A in preparation of drug for treating prostatic cancer | |
| CN103405447A (en) | Application of Chukrasone A in medicaments for treating nasopharyngeal carcinoma | |
| CN103356560A (en) | Application of Sarcaboside B in medicine used for treating prostate cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| CB03 | Change of inventor or designer information |
Inventor after: Wang Zhihong Inventor before: Wu Junhua Inventor before: Liu Yang Inventor before: Huang Rong Inventor before: Wang Hui Inventor before: Zhang Guang Inventor before: Jiang Chunping |
|
| COR | Change of bibliographic data | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20160105 Address after: 262100 Anqiu Municipal People's Hospital, Anqiu health Road, Shandong, 246, China Applicant after: Wang Zhihong Address before: 210093 Nanjing, Gulou District, Jiangsu, No. 22 Hankou Road Applicant before: Nanjing University |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160203 Termination date: 20160829 |